Lifecore Biomedical, Inc. (LFCR) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-281.7%

-$11.61

vs $6.39 price

Levered DCF

$7.64

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

-0.14

Distress zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-8.89×	-5.29×	14.41×	-2.39×	-2.49×	-10.69×	-8.27×	125.94×
P/B	-19.16×	175.14×	15.14×	-56.23×	3.31×	1.73×	1.37×	0.99×
P/S	2.1×	1.82×	1.34×	2.3×	2.61×	3.48×	1.97×	0.48×
EV / EBITDA	48.19×	-40.46×	8.34×	-9.99×	41.86×	-572.8×	-74.97×	17.37×
Gross margin	31.4%	31.3%	32.6%	27.1%	35.1%	38.6%	24.6%	14.5%
Operating margin	-1.0%	-13.4%	-6.9%	-21.1%	-10.6%	-8.7%	-16.2%	-1.4%
Net margin	-23.8%	-30.0%	9.4%	-96.4%	-104.9%	-32.0%	-23.9%	0.4%
Current ratio	3.49×	2.84×	2.08×	2.39×	0.66×	1.46×	0.96×	0.97×
Debt / equity	-10.04×	97.92×	11.81×	-26.63×	2.82×	1.06×	0.96×	0.56×
Interest coverage	0.57×	-0.79×	-0.49×	-1.23×	-0.76×	-0.99×	-5.57×	-1.53×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	216.8%	-2898.0%	106.2%	2353.7%	-132.9%	-15.9%	-16.5%	0.8%
Return on invested capital	-0.6%	-8.1%	-3.9%	-10.1%	-3.7%	-1.6%	-3.9%	-1.1%
Return on assets	-13.3%	-16.2%	4.7%	-39.3%	-42.5%	-6.4%	-7.1%	0.4%
Free cash flow yield	2.3%	-5.8%	-10.6%	-16.4%	-18.1%	-2.5%	-13.8%	-10.7%
Earnings yield	-11.3%	-16.5%	7.0%	-41.9%	-40.1%	-9.2%	-12.1%	0.8%
Enterprise value	$397.2M	$356.5M	$296.4M	$331.4M	$537.6M	$565.4M	$536.9M	$418.6M
Net debt / EBITDA	15.18×	-13.91×	3.52×	-2.82×	19.21×	-217.53×	-30.83×	6.28×
Cash conversion cycle (days)	191	223	189	193	242	426	218	46